Non Small Cell Lung Cancer Metastatic Clinical Trial
Official title:
Phase II Trial of Chemoimmunotherapy With 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
The purpose of this study is to determine whether the combination of a 5-Fluorouracil (5-FU) and interferon, which is able to stimulate the immune system to kill cancer cells, will help to increase tumor shrinkage in previously-treated metastatic gastrointestinal, kidney, or lung Cancer.
Interferon with continuous infusion 5-Fluorouracil (5-FU) regimens have shown response rates ranging from 0-43% in various cancers. Monthly bolus 5-FU + interferon-alfa-2b has not undergone formal phase II testing. In a small pilot study, a 5 consecutive day schedule of 5-FU and interferon-alfa-2b resulted in the limiting toxicities of diarrhea and mucositis. A more limited schedule was recommended. Therefore, it is reasonable to examine such a schedule. In the current study, 5-FU will be followed by interferon-alfa-2b daily for 3 days to attempt to benefit from both the biochemical and immunologic mechanisms described above. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03168464 -
Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05117242 -
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
|
Phase 2 | |
| Completed |
NCT04470440 -
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
|
||
| Completed |
NCT03304093 -
Immunotherapy by Nivolumab for HIV+ Patients
|
Phase 2 | |
| Terminated |
NCT04069936 -
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT03307785 -
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
|
Phase 1 | |
| Recruiting |
NCT06100796 -
Effect of DM on Outcomes and Response Rate in Patients With Advanced NSCLC on ICI
|
||
| Recruiting |
NCT03533127 -
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT04187768 -
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
|
||
| Active, not recruiting |
NCT04951583 -
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT03133546 -
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)
|
Phase 2 | |
| Completed |
NCT03845270 -
Her2-positive Lung Cancer Treated With Dedicated Drug
|
Phase 2 | |
| Recruiting |
NCT05864794 -
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
|
N/A | |
| Recruiting |
NCT05274451 -
A Study to Investigate LYL797 in Adults With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03774732 -
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04621188 -
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
|
Phase 2 | |
| Recruiting |
NCT06378892 -
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
|
Phase 2 | |
| Active, not recruiting |
NCT03235765 -
Cancer Panel From Blood of Lung Cancer Patients
|
||
| Not yet recruiting |
NCT03732482 -
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT02978404 -
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
|
Phase 2 |